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Abstract
Microglia, as intrinsic immunoeffector cells of the
central nervous system (CNS), play a very sensitive,
crucial role in the response to almost any brain
pathology where they are activated to a phagocytic
state. Based on the characteristic features of activated
microglia, we investigated whether these cells can be
visualized with magnetic resonance imaging (MRI )
using ultrasmall superparamagnetic iron oxides (US-
PIOs). The hypothesis of this study was that MR
microglia visualization could not only reveal the extent
of the tumor, but also allow for assessing the status of
immunologic defense. Using USPIOs in cell culture
experiments and in a rat glioma model, we showed that
microglia can be labeled magnetically. Labeled micro-
glia are detected by confocal microscopy within and
around tumors in a typical border- like pattern. Quanti-
tative in vitro studies revealed that microglia internalize
amounts of USPIOs that are significantly higher than
those incorporated by tumor cells and astrocytes.
Labeled microglia can be detected and quantified with
MRI in cell phantoms, and the extent of the tumor can be
seen in glioma-bearing rats in vivo. We conclude that
magnetic labeling of microglia provides a potential tool
for MRI of gliomas, which reflects tumor morphology
precisely. Furthermore, the results suggest that MRI
may yield functional data on the immunologic reaction
of the CNS. Neoplasia (2001) 3, 489–499.
Keywords: microglia, MRI, glioma, magnetic cell labeling, superparamagnetic iron oxides
(USPIO ).
Introduction
The rapid development of molecular biology has been
paralleled in recent years by dramatic advances in the
different imaging modalities for the visualization of cellular
and even molecular processes (molecular imaging) [1–3].
Up to this point, functional imaging data have been obtained
on gene expression [4–6], gene transfer [7 ], enzyme
activity [8,9 ], receptor distribution [10], cell migration
[11,12], and neuronal plasticity using magnetic resonance
imaging (MRI), near- infrared fluorescence [13], biolumi-
nescence, positron emission tomography (PET) [14], and
microPET [15,16].
Of these imaging modalities, MRI provides not only the
best soft - tissue contrast, but also excellent spatial reso-
lution that comes close to the cellular level, with a voxel size
of 10 m in vitro and 50 m in vivo [17–19]. The present
study was undertaken to determine the extent to which MRI
can specifically depict resident microglia of the brain and
invading macrophages involved in the pathology of gliomas.
Microglial cells represent one major intrinsic component of
the central nervous system (CNS) immune response, and
they are extremely sensitive to many pathologic processes.
As resident immunomodulating and phagocytosing cells,
microglia show an instant reaction and thus participate in the
CNS response to several neurologic disorders, including
tumors, inflammation, trauma, and neuronal degeneration
[20]. On activation, microglial cells transform from a ramified
resting state into a reactive amoeboid state. This leads to
complex changes in their physiologic and morphologic
properties, with a substantial increase in phagocytic capacity
[21]. Morphometric investigations revealed a significant
increase in macrophages and microglia within malignant
gliomas (up to 50% of the viable tumor mass), and it has also
been reported that activated microglia are prominent in the
border area and adjacent brain tissue [22–24]. Most studies
of microglia have been performed with cell cultures or at the
histologic level, and only a few PET studies have so far
investigated the in vivo visualization of microglia [14,25].
In recent years, numerous studies have been published on
the use of different iron oxide preparations for specific
magnetic labeling and in vivo tracking of cells by MRI
[26,27]. These studies demonstrate that dextran-coated
ultrasmall superparamagnetic iron oxides (USPIOs) are
predominantly taken up by peripheral macrophages/mono-
cytes, and to a lesser extent by other cell types [28–30]. It
has also been shown that cellular uptake occurs after IV
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injection of the particles, and that MR visualization of
experimental gliomas is improved by these methods
[31,32]. However, virtually no study to date has been
performed to evaluate the role of isolated microglia. More-
over, in prior studies, it remained unclear whether intra-
tumoral USPIO was taken up by glia, peripheral tumor-
associated macrophages, or tumor cells [33,34].
This study was designed to test the utility of USPIOs for
selectively labeling these cell fractions. Using an exper-
imental glioma model, we investigated the intratumoral
distribution of USPIO in the different cell types, and the
detection of magnetically labeled microglia /macrophages by
MRI. This study has clinical implications for understanding
intensity changes of an MR signal in brain tumors following
administration of USPIOs, and will shed light on previously
open questions regarding the intratumoral distribution of
these particles. Because microglia are an important compo-
nent of the CNS immune response, this technique may also
provide in vivo information on the immunologic status of the
CNS in the presence of brain tumors as well as on the
therapeutic response.
Materials and Methods
Cells
Microglial cells were prepared from the cortex of newborn
Naval Medical Research Institute rats, essentially as
described previously [35,36]. In brief, cortical tissue was
carefully freed from blood vessels and meninges. Tissue was
trypsinized for 2 minutes, carefully disintegrated with a fire-
polished pipette, and washed twice. The cortical cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum, and the medium
was changed every third day. After 9 to 12 days, microglia
were separated from the underlying astrocytic monolayer by
gentle agitation. Microglial cells in the supernatant were
washed once and plated onto poly-L- lysine–coated glass
coverslips at a density of 105 cells /coverslip for microscopy,
and into 96-well plates with 2104 cells /well for quantitative
analysis. Purity of microglial cells was tested by labeling with
lectin from Griffonia simplicifolia [ Isolectin -B4 ( IL-B4);
Sigma Chemical Co., Deisenhofen, Germany] and anti-
bodies against glial fibrillary acidic protein (DAKO, Glostrup,
Denmark). Cultures typically had a microglial content of
more than 95%.
Rat C6 glioma cells, 9L gliosarcoma cells, F98 glioma cell
line, and monocytic cell line P-388D1 were obtained from
commercial sources and cultured under previously described
standard conditions [37]. Rat macrophages were obtained
by peritoneal lavage with 11.6% sucrose solution after the
rats had been put to death. Cells were washed twice with
Hank’s balanced salt solution and cultured in a macrophage
serum-free medium (Gibco-BRL, Grand Island, NY).
Magnetite Synthesis and Labeling
Dextran-coated USPIO was prepared and kindly pro-
vided by M. Kresse ( Institut fu¨r Diagnostikforschung, Free
University Berlin, Germany) using a procedure originally
described by Hasegawa et al. [38]. This USPIO preparation
has a total iron carboxydextran ratio of 0.92 g/g, a core
diameter of 6.5 nm, and a hydrodynamic diameter of
31.3±15.8 nm. The relaxivities are R1=34.1 l /mmol per
second andR2=61.4 l /mmol per second with anR2 /R1 ratio
of 1.8. The volume of distribution is 0.05±0.00 l /kg and the
plasma clearance is 0.81±0.0 ml /min per kilogram with an
iron blood half life of 0.64±0.04 hours.
Iron oxides were fluorescein- labeled with either Tex-
asRed-hydrazide or 5-( ( (2- (carbohydrazino)methyl )th-
io)acetyl )aminofluorescein (Molecular Probes, Eugene,
OR). USPIO was activated for 30 minutes with sodium
metaperiodate (NaIO4) dissolved in 0.025 M citrate buffer
(pH 5). After purification over a citrate buffer–equilibrated
chromatography column (Sephadex G-25, PD-Column;
Sigma-Aldrich, Deisenhofen, Germany), the eluent was
incubated for 2 hours with one of the fluorescent dyes.
Stabilization of the labeling was achieved by twice adding
20 mg sodium cyanoborohydride after 2 hours. Following
separation of unbound dye by renewed column chroma-
tography, the fluorescence- labeled USPIO was sterilely
filtered and stored at 48C.
Confocal Fluorescence Microscopy
Immediately before the experiment, excess medium
covering the cells was aspirated, and the cells were
incubated for different time periods and at varying concen-
trations of fluorescence- labeled USPIO and culture medium.
The medium was then removed, and the cells were washed
as before. During the entire procedure, all media were
maintained at 378C.
The coverslips containing the cells were mounted in a
specially designed microscopic observation chamber, which
allows for continuous rinsing of the cells with buffered
solution during in vivo microscopy. The chamber was
installed on the stage of a confocal argon laser scanning
microscope (Sarastro 2000; Molecular Dynamics, Sunny-
vale, CA). The scanner was mounted on an upright micro-
scope (Axioscope; Zeiss, Oberkochen, Germany) equipped
with a 40 magnification, numerical aperture 0.75, water
immersion objective. Acquisition of the fluorescence data
and image analysis was performed using ImageSpace
(Molecular Dynamics) and standard PC evaluation software.
Quantification of Cellular Uptake
Microglial cells and peritoneal macrophages were incu-
bated in 96-well plates with fluorescein- labeled USPIO at
various concentrations (15, 75, 150, 300, 600, 750 M, 1.5,
3, 6, 9, 12, 15, 18 mM), and for different time periods (15, 30,
45, 60, 90, and 120 minutes), and were then washed twice
with phosphate-buffered saline. Quantitative analysis was
conducted with a fluorescence reader (1420 Victor; Wallac
Oy, Turku, Finland) at an excitation wavelength of 485 nm
and an absorption wavelength of 535 nm. Due to short
excitation times and very stable fluorescent compounds, no
signal alteration caused by photobleaching was observed.
Repeated measurements delivered identical results. USPIO
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uptake by cell lines (C6, 9L, F98, and P-388D1) and
astrocytes (1.5, 3, and 6 mM) was determined using
inductively coupled plasma atomic emission spectrometry
( ICP-AES) after lysis with concentrated HNO3. The dis-
played iron uptake data are the total cellular iron after
incubation, minus the baseline iron content of control cells.
Rat Glioma Model
A rat glioma model with enhanced green fluorescent
protein (eGFP)- transfected F98 cells was used for the
characterization of USPIO labeling of microglia and invading
blood macrophages under pathologic conditions in an in situ
environment.
To induce intracerebral tumors, male, 7-week-old
Fischer CD 344 rats (Charles River Breeding Laboratories,
Wilmington, MA) weighing 150 to 170 g, were anesthetized
with an intramuscular injection of 50 mg/kg body weight of
ketamine HCl 10%, and 2mg/kg body weight of xylazine HCl
2%. The animals were immobilized in a stereotactic frame. A
linear skin incision was made over the bregma, and a 1-mm
burr hole was drilled into the skull approximately 2 mm
posterior and 4 mm lateral to the bregma. A 10-l (30 G)
gas- tight Hamilton syringe was then used to inject 10 l of
the F98 cell suspension (5105 cells in serum-free DMEM)
into the putamen at a depth of 4 mm from the dural surface.
The injection was done slowly over 5 minutes and the needle
was withdrawn slowly over another 5 minutes. The burr hole
was occluded with bone wax (Ethicon, Somerville, NJ) to
prevent leakage of cerebrospinal fluid, and the skin was
closed with nonmagnetic sutures.
For improved microscopic differentiation of glioma cells,
we conducted our experiments with an eGFP-transfected
F98 cell line, kindly provided by S. Kuhn, Max Delbru¨ck
Center for Molecular Medicine, Berlin -Buch, Germany.
Immunohistochemistry and USPIO Labeling of Native Brain
Slices
Vibratome brain slices of the glioma-bearing brains were
assessed for the uptake of iron oxide by CNS macrophages,
tumor cells, and healthy brain tissue.
Ten to 14 days after inoculation with F98 tumor cells,
rats were decapitated, the brain was removed, and the
forebrain was cut into 120-m-thick coronal slices, which
were kept in bicarbonate-buffered Ringer’s solution until
further processing. For qualitative analysis of microglia
USPIO labeling, brain slices were incubated with Tex-
asRed- labeled USPIOs (3 mM) for 30 minutes, followed
by rinsing of the slices and carried out as described above
for cultured cells.
To distinguish microglia in glioma brain slices, we
performed macrophage- and microglia -specific immuno-
fluorescence staining of the complement 3 receptor (CR3)
with OX-42 antibody. The native slices were incubated
with OX-42 antibodies (1:150; Serotec, Oxford, UK) for
90 minutes at 378C. After three washes in bicarbonate-
buffered saline solution, the slices were fixed with 4%
paraformaldehyde for 1 hour and then permeabilized with
blocking buffer (0.1% Triton-X 100, 2% horse serum, and
5% goat serum in 0.1 M phosphate buffer ) for 1 hour at room
temperature. For visualization, a Cy3-coupled secondary
antibody (goat-anti -mouse IgG, 1:250; Dianova, Hamburg,
Germany) was added for 1.5 hours. Antibodies were diluted
in blocking buffer. After three washes, slices were mounted
in moviol and examined by confocal microscopy.
Phantom MRI
MRI was performed with a 1.5-T superconducting
magnet (Siemens Vision, Erlangen, Germany) using a
human knee coil. The imaging protocol consisted of a
coronal T2*-weighted FLASH 3D gradient -echo sequence
(TR/TE 34/20 msec, flip angle 158, FOV 8080 mm, slice
thickness 1 mm). Phantoms were prepared with varying
amounts of USPIO- labeled microglial and monocytic P-
388D1 cells (0.25, 0.5, 1.0, 1.5, 2.0, and 3.0 million cells ),
dissolved in 100 l 4% gelatin following incubation of the
cells for 1.5 hours with 3 mM USPIO in culture. The cell
solution was embedded in 2% agar-agar wells with 0.02%
Magnevist (Schering AG, Berlin, Germany) for a stand-
ardized background signal, and covered with an additional
200 l of 4% gelatin. Standard phantoms were produced in
the same way with different concentrations of free USPIO
dissolved in 100 l gelatin. Analysis was performed with
NIH image software.
In Vivo MRI and Histology
Tumor-bearing rats (n=6) as described above were
imagedwith the sameMRscanner and T2*-weighted FLASH
3D gradient -echo sequence (TR/TE 34/20 msec, flip angle
158, FOV100100mm,slice thickness1mm).The first series
of imageswastaken14daysaftertumorimplantation.Twenty-
four hours after administration of 300 mol USPIO/kg body
weight, imaging was repeated. Additionally, a T2-weighted
turbospinechosequence(TR/TE4500/96msec,angle1808,
FOV 100100 mm, slice thickness 2 mm) was conducted.
Animalswereperfusedwithformalin,andkryosections(10m)
were prepared. Corresponding brain slices were stained with
HE, DAB-enhanced Pearl’s Blue reaction, and OX-42 anti-
bodyasdescribedabove.
Results
Microglia /Macrophages are Labeled by Iron Particles in a
Rat Glioma Model
After USPIO incubation (3 mM for 30 minutes) of the
freshly prepared glioma brain slices, confocal microscopy
revealed a massive uptake of TexasRed- labeled USPIOs
by microglia and macrophages, and almost no detectable
uptake by glioma cells. Gliomas could be detected by
labeled microglia /macrophages surrounding and infiltrating
the tumor (Figure 1C and D ). USPIO was predominantly
taken up by amoeboid microglia. Ramified resting micro-
glia showed no evident USPIO incorporation in contrast to
activated microglia /macrophages, which have a high
phagocytic capacity (Figure 1B ). It was even possible to
detect single infiltrating tumor cells that were encircled by
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labeled microglia and macrophages (Figure 1D, inset ). As
an indicator for the activated state of microglia in the
tumor region, phagocytic cells migrated rapidly to the
surface of the slice and took up USPIOs during
incubation.
Distribution of magnetically labeled microglia /macro-
phages could be confirmed with immunohistochemistry:
labeling of microglia and invading blood macrophages with
the OX-42 antibody, which recognizes CR3, demonstrates a
diffuse distribution of OX-42–positive cells within the tumor
(blue in Figure 1A ). A native slice of the tumor region shows
the eGFP- labeled tumor cells (green in Figure 1A, inset ).
The amount of CR3-positive cells within a tumor varied
depending on its individual morphology. The tumors were
encircled at the border by a more or less dense zone of
microglia and macrophages.
These observations suggest that labeling of microglia /
macrophages with USPIOs reproduces the distribution of
these cells within and around a tumor, and that labeled
microglia /macrophages can be used to identify and deter-
mine the extent of gliomas.
USPIO is Preferentially Taken Up by Microglia in Mixed
Culture
Because we could detect almost no USPIO uptake by
other cells of the CNS and tumor cells in the slice experi-
ments, we studied uptake capacity in comparison to micro-
glia under cell culture conditions.
Astrocytes are involved in the CNS pathology and may
potentially also perform endocytosis. Therefore, astrocytes
were directly compared to microglia regarding their capacity
to incorporate USPIOs. Cells were assessed in a co-culture
with microglial cells growing on a monolayer of astrocytes.
Under such identical conditions, uptake by microglia is
evident, whereas there is almost no detectable uptake by
astrocytes. This underlines the importance of microglia as
phagocytic cells in the CNS. All photomicrographs in Figure 2
show the same field of view at different cell levels. A and B
document the confocal cell level of microglia, and C and D
Figure 1. Activated microglia and invading macrophages infiltrate the tumor region in rat gliomas and show rapid uptake of USPIO in a slice model. Brain slices
( 150 m thick ) of the tumor region were incubated with 3 mM TexasRed USPIO for 30 minutes, and investigated in the confocal microscope with varying
magnifications. (A ) OX -42 staining (blue ) reveals the proportion of microglia and invading macrophages within the tumor. The inset displays green eGFP -
transfected tumor cells in an unlabeled slice. (B ) After incubation of slices with TexasRed - labeled USPIO, the magnetite was clearly localized intracellularly, and
predominantly within OX -42–positive ameboid cells ( inset in B; USPIO red, OX -42 blue ). OX -42–positive microglia with a resting ramified appearance (blue )
showed no significant USPIO uptake. (C ) Visualization of microglia and macrophages by intracellular labeling with TexasRed - stained USPIO showed diffuse
infiltration of the tumor, as seen in (A ). (D ) Formation of a border around the tumor, differentiating the tumor from healthy brain tissue, was also detectable by USPIO
labeling. A single tumor cell encircled by USPIO - labeled macrophages could be detected at a distance from the main tumor mass ( inset in D ).
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the level of astrocytes. B andDwere taken after incubation of
the co-culture with 3 mM USPIO for 30 minutes.
A co-culture study of microglia with F98 tumor cells again
revealed massive incorporation of USPIOs by microglia, and
Figure 3. Labeling of co - cultured microglia and F98 tumor cells with TexasRed -USPIO confirmed the results of glioma slice experiments. (A ) Due to the
incorporated iron oxide, microglial cells can be detected with confocal microscopy after incubation with 3 mM USPIO for 30 minutes. F98 cells do not incorporate
USPIO. (B ) Corresponding phase - contrast photograph showing the F98 cells ( arrows ) between the microglia. (C ) Labeling with Isolectin -B4 after incubation
identifies phagocytosing cells to be microglia.
Figure 2. Visual comparison of USPIO uptake by microglia and astrocytes under identical conditions. Confocal microscopy of a microglia - astrocyte co - culture. All
photomicrographs display the same field of view, but are focused on two different cell levels. (A ) and (B ) are focused on microglia attached to the astrocytes. (C )
and (D ) are focused on the astrocytic monolayer beneath the microglia. Phase - contrast photographs focusing on each cell type show cell morphology (A and C ).
After incubation with 3 mM TexasRed - labeled USPIO for 30 minutes, (B ) and (D ) display intracellular uptake predominantly by microglia.
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no detectable uptake by the tumor cells after incubation with
3 mM USPIO for 30 minutes (Figure 3 ). Microglial cells were
counterstained with IL-B4 to distinguish them from the tumor
cells (Figure 3C ).
Thus, microglia can be magnetically labeled with iron
oxides and, through their intracellular USPIO content, can be
distinguished from other cells involved in glioma pathology
under in vitro conditions, as well.
Characterization of the intracellular distribution of iron
oxides with confocal microscopy revealed that USPIOs
labeled with TexasRed fluorescence dye are arranged in a
typical endosome- like pattern within the microglia cells after
incubation with 3 mM USPIO for 30 minutes (Figure 4 ),
similar to what has been previously described for USPIO
internalization in other cell types [31,39]. Cellular vacuoles
depicted by the phase-contrast technique can be identified
as mainly USPIO-containing organelles of the cells, and
there seems to be no free USPIO in the cytoplasm.
Microscopy studies also revealed that not all microglial cells
internalize equal amounts of USPIO, which is in agreement
with other investigations of microglia phagocytosis [40].
Quantification of USPIO Uptake by Microglia and Tumor
Cells In Vitro
Quantitative analysis of USPIO incorporation by cul-
tured microglia shows both concentration and time
dependencies. Cellular uptake after 30 minutes of incuba-
tion is characterized by a typical logarithmic concentration-
dose response. The concentration range between 1.5 and
12 mM is associated with the highest rate of incorporation
Figure 4. Intracellular distribution of TexasRed - labeled USPIO incorporated
by microglia. After incubation of cultured microglia with 3 mM TexasRed -
labeled USPIO for 30 minutes, an endosome- like distribution pattern of the
internalized contrast agent can be observed by confocal microscopy. (A )
Phase - contrast, (B ) fluorescent USPIO. Control cells not incubated with
USPIO showed weak autofluorescence ( insets ).
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Figure 5. USPIO incorporation characteristics of cultured microglia. (A )
Concentration dependency: Microglia: cells were incubated at 37 8C in
different concentrations ( 15 M to 18 mM) of TexasRed - labeled USPIO for
30 minutes, and cellular uptake was determined by fluorescence scanning.
Inset displays uptake by identically treated peritoneal macrophages. (B ) Time
dependency: incorporation was quantified after microglia had been incubated
for varying time periods (15 to 120 minutes ) in 3 mM TexasRed - labeled
USPIO.
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by the cells, and saturation seems to occur at a level of 15
to 18 mM USPIO (Figure 5A ). Invading blood macro-
phages are another important phagocytic cell population
involved in CNS pathology. Their specific capacity to
phagocyte USPIOs in comparison to microglia was likewise
assessed under in vitro conditions. Incubation of cultured
peritoneal macrophages as an equivalent cell type also
revealed a concentration-dependent uptake of USPIOs
similar to that seen in microglia (Figure 5A ).
Assessment of USPIO uptake by microglial cells at a
constant concentration of 3 mM, but for different time periods
(15 to 120 minutes), showed an almost linear correlation
within this time interval (Figure 5B ). As the exact amount of
USPIO uptake fluctuates among different experiments,
depending on many factors that influence cell activation,
the results of USPIO uptake by microglia are presented in a
semiquantitative manner. Because microglial cells seem to
incorporate huge amounts of iron oxides, the influence of
USPIO phagocytosis on cell viability was assessed using a
commercial assay. Cell survival depended on magnetite
concentration and incubation time, which was also confirmed
by microscopic time- lapse video observation (not shown
here). USPIO — in the concentrations used in this study —
was not toxic for cells, but further increases in concentration
or incubation times led to uninhibited USPIO incorporation,
with swelling of the cells and consecutive cell death as
observed by microscopy.
Figure 6 summarizes the quantitative uptake of USPIO by
different CNS tumor cell lines (9L, C6, and F98), a monocytic
cell line (P-388D1), and isolated astrocytes. The amount of
USPIO incorporated was determined by direct measurement
of intracellular iron levels using ICP-AES. Uptake of iron
oxides by all cell types was concentration-dependent (1.5,
3, and 6 mM), and ranged from 26 ng to nearly 1000 ng Fe/
106 cells. As expected, uptake was highest for the monocytic
cell line, which is known to have a high phagocytic activity. In
comparison, isolated astrocytes incorporated substantially
lower amounts of USPIO, but significantly more than the
tumor cell lines studied. These results are consistent with
previous investigations using slightly different paramagnetic
particles and other cell types [27,32].
Cultured, Iron-Labeled Microglia /Macrophages Can be
Detected by MRI in a Phantom Model
To assess if USPIO- labeled microglia and macrophages
can be detected by MRI, gel phantoms containing magneti-
cally labeled cells were prepared and examined with a
conventional 1.5-T scanner. Cell phantoms were arranged
in such a way as to simulate a tumor- like condition in terms
of the amount of microglial cells and macrophages within the
tumor mass. Even with a conventional human imaging
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Varying concentrations ( 0.25106, 0.5106, 1106, 1.5106, 2106, and
3106 ) of microglia and P -388D1 cells were incubated for 1.5 hours with 3
mM USPIO, and embedded in 100 l of 4% gelatin. (B ) Analysis of the
standardized MRI signal revealed similar USPIO uptake by cultured microglia
and macrophages (P -388D1 ).
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Figure 6. Concentration dependency of USPIO incorporation in different
cultured cell types involved in glioma pathology. Cultured cell lines [C6, 9L,
F98 (glioma ), and P-388D1 (monocytic ) ] and primary astrocytes were
incubated in unlabeled USPIO for 30 minutes at varying concentrations (1.5 to
6 mM), and cellular uptake was determined as the intracellular iron level by
means of ICP -AES.
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Figure 8. In vivo distribution of USPIO in glioma -bearing rats. MRI (A ) before ( I, II ) and after ( III, IV ) administration of USPIO reveals a massive accumulation of
iron oxides within the tumor, seen as a signal intensity decrease. Immunohistology [B( III and IV ) ] confirms predominant USPIO uptake ( red ) by macrophages and
microglia ( blue ), also under in vivo conditions. T2* -weighted 3D FLASH sequence (TR /TE 34 /20 msec, flip angle 15 8 ) is displayed in I and III; T2 -weighted turbo
spin echo sequence (TR /TE 4500 /96 ) in II and IV. Imaging was performed before and 24 hours after administration of 300 mol / kg USPIO. Through DAB staining,
image [B( II ) ] confirms iron deposition within and around the tumor. HE staining of corresponding slice [B( I ) ]. OX -42 staining detects high proportion of microglia
and macrophages ( red ) within the tumor ( green ) [B( III ) ]. Also after in vivo administration, USPIO ( red ) can predominantly be found in the macrophages and
microglia [B( IV ) ].
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system, it was possible to detect the labeled primary
microglia, and to correlate the received signal intensity with
varying cell concentrations. The received signal intensity
within the cell phantom decreased with increasing concen-
trations of embedded cells per well (0.25, 0.5, 1.0, 1.5, 2.0,
and 3.0 million cells /100 l ), representing higher amounts of
USPIO per well. Labeled microglia could be detected by MRI
by altering the received signal intensity starting at the lowest
concentration of 0.25106 cells, corresponding to 0.8 g of
pure USPIO in the standard phantom (Figure 7A ). Imaging
of an identically prepared P-388D1 cell phantom yielded
similar results, with signal intensity also correlating to the
concentration of labeled cells. Quantitative analyses
revealed an analogous signal intensity in both cell types at
identical cell concentrations (Figure 7B ).
USPIO Distribution and MRI After In Vivo Administration
MRI of a glioma-bearing rat displays a huge tumor with a
size more than the right hemisphere (Figure 8 ). After
administration of USPIOs, a significant signal intensity
decrease in T2*-weighted pictures can be seen, which
reflects the extent of the tumor and correlates quite well to
the perifocal edema [A( II ) ]. An inhomogeneous intratumoral
signal pattern occurs due to necrosis and varying distribution
of microglia and macrophages within the tumor. The tumor
border, demarcated by microglia, can be precisely differ-
entiated from the healthy brain tissue.
Confocal microscopy analysis reveals that the intra-
venously administered TexasRed- labeled USPIOs (red)
can be found in microglia and macrophages (blue), and
hardly at all in tumor cells (green) [B( III ) ]. On exact
observation, an identical intracellular perinuclear distribution
pattern, as seen in cultured microglia (Figure 4 ), can be
detected. Again, the tumor mass consists of a high amount of
these immunologic cells. After DAB-enhanced iron staining,
USPIOs can be found within and around the tumor in a
border- like pattern corresponding to the fluorescent pictures
and MRI [B( II ) ].
In conclusion, detection of gliomas with MRI and iron
oxides is predominantly based on the visualization of the
labeled microglia and macrophages, and not the tumor cells
themselves.
Discussion
Nearly any kind of pathologic CNS process leads to an
activation of microglia and a change of their cellular proper-
ties. Making use of the markedly increased phagocytic
capacity as the characteristic immune function of activated
microglia, magnetic labeling of this cell type with a sensitive
MR marker may have the potential to improve detection of
CNS pathology by MRI. We have demonstrated for the first
time that: 1) microglia can be labeled with magnetic particles,
2) microglia possess the highest labeling capacity in
comparison to other cell types involved in glioma pathology,
3) labeled activated microglia very precisely represent the
tumor morphology, and 4) labeled microglia can be detected
with MRI in vitro and in vivo.
It is well known, and has been described by other groups
using C6 and RG2 glioma models, that gliomas are infiltrated
by macrophages and differ from each other only in the
intratumoral distribution patterns of these macrophages
[41–44]. Morphometric studies of phagocytic infiltration in
human gliomas identified amounts ranging between 20%
and 40% of the tumor cell mass [45,46]. Our investigation
confirms that rat F98 gliomas are infiltrated by a huge
proportion of OX-42–positive microglia /macrophages.
Although microglia, as the main intrinsic immunoeffector
cells of the CNS, are primarily thought to be involved in
immune defense, recent investigations suggest that micro-
glia promote rather than inhibit the invasive and proliferative
properties of gliomas by cytokine secretion ( IL-10) [47–49].
For this reason, glioma cells seem to even secrete cytokines
that attract microglia in a kind of symbiotic reaction [41,50].
Although it is not possible to differentiate clearly between
microglia and invading macrophages, both cell types seem to
participate in the CNS immune response.
Whereas preliminary investigations suggested that cul-
tured microglial cells are able to incorporate USPIOs [51],
this has never been demonstrated. In contrast, labeling of
other immune cells, such as macrophages and lymphocytes,
with slightly different types of USPIO has been shown by
different groups to be possible [27,39,52]. Cells other than
professional phagocytes and immune cells, such as tumor
cells, are also able to incorporate iron oxides [31,32]. Our
study shows that cultured microglial cells can be labeled very
effectively with dextran-covered iron oxides. The observed
intracellular uptake of such USPIO particles with an endo-
some- like distribution pattern, as well as the centripetal
movement of the vesicles toward the perinuclear space after
plasma membrane invagination, corresponds to the afore-
mentioned observations made in other cell types.
Recent work by A. Moore describes USPIO uptake in
tumor cells and tumor-associated macrophages. Uptake in
tumor cells appeared to be directly proportional to cellular
proliferation rates [34]. Though we could also prove uptake
by tumor cells in culture, it was much higher in microglia /
macrophages. Confocal microscopy of co-cultured microglia
and astrocytes showed that USPIO is predominantly taken
up by microglia. The fact that USPIO uptake by astrocytes is
still higher than incorporation by the investigated tumor cell
lines (F98, 9L, and C6), underlines the extraordinary position
of microglia regarding their phagocytic capacity, and thus
their potential for USPIO labeling among the cell types
involved in glioma pathology.
Our in situ experiments in glioma slice preparations
confirmed the cell culture findings of extensive USPIO
incorporation by activated microglia and macrophages, and
almost no detectable uptake by tumor cells. USPIO labeling
of microglia and macrophages occurred only in areas of CNS
pathology, whereas resting microglia and other cell types in
healthy brain tissue showed no USPIO uptake. By labeling of
microglia and macrophages with fluorescence-stained
USPIOs, it was thus possible to detect gliomas and to
differentiate them from unaffected surrounding tissue. Even
solitary invading tumor cells encircled by labeled microglia
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but far away from the main tumor mass could be identified
microscopically.
Regarding the question as to which kind of macro-
phages was labeled with USPIOs [33], we could exclude
predominant labeling of endothelial cells. Nevertheless, an
exact differentiation between invaded blood macrophages
and activated microglia remains difficult. Because both cell
types show similar USPIO uptake patterns, the exact
determination of their origin is of minor importance for our
investigations.
Most of the commonly used MRI contrast agents based
on gadolinium conjugates are not specifically taken up by
any kind of cell, and signal enhancement is mainly caused by
interstitial accumulation or increased vascularization. Thus,
MRI is still limited in terms of exact delineation, early
detection, and tissue differentiation. Our investigations
demonstrate that the distribution of incorporated USPIOs
within glioma slices represents the region of activated
microglia and immigrated macrophages. As described by
Roggendorf et al. [23], gliomas are frequently surrounded by
microglia and macrophages in a border- like pattern. This
property, extremely helpful for localizing the exact tumor
border, was also detected in the tumors studied here. Our
studies of magnetically labeled microglial cells embedded in
gelatin phantom models demonstrated that it is possible to
visualize these cells by MRI. Furthermore, the received
signal intensity displayed the incorporated amount of
contrast medium or the amount of cells within the phantom.
Gradient -echo sequences, having an extremely high sensi-
tivity for iron, offer the possibility to detect iron amounts as
low as 62.2 ng/mm3 as shown in previous studies [53]. After
in vivo administration, MRI of magnetically labeled microglia
and macrophages depicted the glioma extent very precisely.
Intravenous injection in human adults of a normal dose of
2.5 mg (45 mol) Fe/kg body weight results in a blood
concentration of 70 g/ml (1.4 mM), assuming a 70-kg
subject (7% blood volume and 46% hematocrit ). At this
dosage and a given blood half - life of 40 to 80 minutes,
exposure of activated microglia and invaded macrophages to
USPIOs should be sufficient for their effective labeling in
vivo, as seen here. Under in vivo conditions, there exists no
risk of significant cell damage when such a physiologic
dosage is administered [54].
Precise visualization of gliomas is the most important
prerequisite for initiating and performing any kind of therapy.
Early detection of disease would prevent an unnecessary
delay in intervention and, as demonstrated here, it might
even be feasible to visualize single infiltrating cells far away
from the main tumor. Because such minimal lesions are not
necessarily associated with a blood–brain barrier disruption,
a mechanism must be introduced to transfer USPIOs across
this natural barricade. One possibility is to conjugate USPIOs
with a ligand, permitting specific transport and incorporation.
This procedure additionally increases cell labeling specificity
and uptake rates, as demonstrated by previous investiga-
tions [55]. The fact that predominantly highly activated
microglial cells have phagocytic activity could make it
possible to detect even minimal lesions.
Microglia activation and invasion of macrophages also
play an important role in several other CNS diseases. Acute
and chronic inflammation induces a pronounced immune
response including microglial activation [56]. Magnetic
labeling of microglia /macrophages provides the potential
for detection of any kind of inflammatory focus, or for staging
of disorders such as multiple sclerosis [57]. Furthermore,
immunologic information could be gained for therapeutic
follow-up, and possibly for new treatment strategies.
Specific labeling of peripheral cells such as T lymphocytes
could complement such immunologic interaction [58].
Based on these promising data, one should focus on
microglia and invading macrophages when labeling cells with
intracellular contrast agents for MRI of CNS pathology.
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